{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:34:40Z","timestamp":1790822080165,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-09451-4","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:07:20Z","timestamp":1767784040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhancing the breadth of protection in mice with a multivalent influenza vaccine"],"prefix":"10.1038","volume":"9","author":[{"given":"Xiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangteng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6076-2547","authenticated-orcid":false,"given":"Man","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5989-7591","authenticated-orcid":false,"given":"Dongming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"9451_CR1","unstructured":"WHO. WHO launches new global influenza strategy. https:\/\/www.who.int\/news\/item\/11-03-2019-who-launches-new-global-influenza-strategy."},{"key":"9451_CR2","doi-asserted-by":"publisher","unstructured":"Ermler, M. E. et al. Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model. J. Virol. 91, https:\/\/doi.org\/10.1128\/JVI.00286-17 (2017).","DOI":"10.1128\/JVI.00286-17"},{"key":"9451_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"9451_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50087-5","volume":"15","author":"C Dong","year":"2024","unstructured":"Dong, C. et al. Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines. Nat. Commun. 15, 5800 (2024).","journal-title":"Nat. Commun."},{"key":"9451_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50345-6","volume":"15","author":"D Malouli","year":"2024","unstructured":"Malouli, D. et al. Cytomegalovirus vaccine vector-induced effector memory CD4 + T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge. Nat. Commun. 15, 6007 (2024).","journal-title":"Nat. Commun."},{"key":"9451_CR6","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/S1473-3099(14)70831-X","volume":"14","author":"P Gautret","year":"2014","unstructured":"Gautret, P. et al. Emerging viral respiratory tract infections-environmental risk factors and transmission. Lancet Infect. Dis. 14, 1113\u20131122 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"9451_CR7","doi-asserted-by":"publisher","unstructured":"Wu, N. C. & Wilson, I. A. Influenza Hemagglutinin Structures and Antibody Recognition. Cold Spring Harb. Perspect. Med. 10, https:\/\/doi.org\/10.1101\/cshperspect.a038778 (2020).","DOI":"10.1101\/cshperspect.a038778"},{"key":"9451_CR8","first-page":"75","volume":"10","author":"VC Huber","year":"2008","unstructured":"Huber, V. C. & McCullers, J. A. FluBlok, a recombinant influenza vaccine. Curr. Opin. Mol. Ther. 10, 75\u201385 (2008).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"9451_CR9","doi-asserted-by":"publisher","unstructured":"Corbett, K. S. et al. Design of nanoparticulate Group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. mBio 10, https:\/\/doi.org\/10.1128\/mBio.02810-18 (2019).","DOI":"10.1128\/mBio.02810-18"},{"key":"9451_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1126\/science.aac7263","volume":"349","author":"A Impagliazzo","year":"2015","unstructured":"Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301\u20131306 (2015).","journal-title":"Science"},{"key":"9451_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"9451_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/289366a0","volume":"289","author":"IA Wilson","year":"1981","unstructured":"Wilson, I. A., Skehel, J. J. & Wiley, D. C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289, 366\u2013373 (1981).","journal-title":"Nature"},{"key":"9451_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cell.2016.06.043","volume":"166","author":"MG Joyce","year":"2016","unstructured":"Joyce, M. G. et al. Vaccine-induced antibodies that neutralize Group 1 and Group 2 influenza A viruses. Cell 166, 609\u2013623 (2016).","journal-title":"Cell"},{"key":"9451_CR14","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"337","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343\u20131348 (2012).","journal-title":"Science"},{"key":"9451_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1205669","volume":"333","author":"D Corti","year":"2011","unstructured":"Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850\u2013856 (2011).","journal-title":"Science"},{"key":"9451_CR16","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/infdis\/jis935","volume":"207","author":"RB Couch","year":"2013","unstructured":"Couch, R. B. et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J. Infect. Dis. 207, 974\u2013981 (2013).","journal-title":"J. Infect. Dis."},{"key":"9451_CR17","doi-asserted-by":"publisher","first-page":"e02134","DOI":"10.1128\/JVI.02134-18","volume":"93","author":"SR Christensen","year":"2019","unstructured":"Christensen, S. R. et al. Assessing the protective potential of H1N1 influenza virus hemagglutinin head and stalk antibodies in humans. J. Virol. 93, e02134 (2019).","journal-title":"J. Virol."},{"key":"9451_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03243-7","volume":"9","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during fatal H7N9 disease. Nat. Commun. 9, 824 (2018).","journal-title":"Nat. Commun."},{"key":"9451_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1189\/jlb.0313180","volume":"95","author":"T Wu","year":"2014","unstructured":"Wu, T. et al. Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J. Leukoc. Biol. 95, 215\u2013224 (2014).","journal-title":"J. Leukoc. Biol."},{"key":"9451_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1099\/0022-1317-83-1-151","volume":"83","author":"CJ Cohen","year":"2002","unstructured":"Cohen, C. J. et al. Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J. Gen. Virol. 83, 151\u2013155 (2002).","journal-title":"J. Gen. Virol."},{"key":"9451_CR21","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1080\/21645515.2017.1419108","volume":"14","author":"J Guo","year":"2018","unstructured":"Guo, J., Mondal, M. & Zhou, D. Development of novel vaccine vectors: chimpanzee adenoviral vectors. Hum. Vaccines Immunother. 14, 1679\u20131685 (2018).","journal-title":"Hum. Vaccines Immunother."},{"key":"9451_CR22","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/jmv.23546","volume":"85","author":"S Zhang","year":"2013","unstructured":"Zhang, S. et al. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J. Med. Virol. 85, 1077\u20131084 (2013).","journal-title":"J. Med. Virol."},{"key":"9451_CR23","doi-asserted-by":"publisher","first-page":"e0006870","DOI":"10.1371\/journal.pntd.0006870","volume":"12","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. PLoS Negl. Trop. Dis. 12, e0006870 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"9451_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03122-6","volume":"23","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine. J. Nanobiotechnol. 23, 77 (2025).","journal-title":"J. Nanobiotechnol."},{"key":"9451_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41586-024-08054-z","volume":"637","author":"TP Peacock","year":"2025","unstructured":"Peacock, T. P. et al. The global H5N1 influenza panzootic in mammals. Nature 637, 304\u2013313 (2025).","journal-title":"Nature"},{"key":"9451_CR26","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3201\/eid3007.240508","volume":"30","author":"ER Burrough","year":"2024","unstructured":"Burrough, E. R. et al. Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b virus infection in domestic dairy cattle and cats, United States, 2024. Emerg. Infect. Dis. 30, 1335\u20131343 (2024).","journal-title":"Emerg. Infect. Dis."},{"key":"9451_CR27","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMc2405371","volume":"390","author":"TM Uyeki","year":"2024","unstructured":"Uyeki, T. M. et al. Highly Pathogenic Avian Influenza A(H5N1) virus infection in a dairy farm worker. N. Engl. J. Med. 390, 2028\u20132029 (2024).","journal-title":"N. Engl. J. Med."},{"key":"9451_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12396","volume":"270","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y., Garcia-Ibanez, L. & Toellner, K. M. Regulation of germinal center B-cell differentiation. Immunol. Rev. 270, 8\u201319 (2016).","journal-title":"Immunol. Rev."},{"key":"9451_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2290838","volume":"13","author":"P Zhou","year":"2024","unstructured":"Zhou, P. et al. One HA stalk topping multiple heads as a novel influenza vaccine. Emerg. Microbes Infect. 13, 2290838 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"9451_CR30","doi-asserted-by":"publisher","first-page":"100432","DOI":"10.1016\/j.dmpk.2021.100432","volume":"42","author":"F Sakurai","year":"2022","unstructured":"Sakurai, F., Tachibana, M. & Mizuguchi, H. Adenovirus vector-based vaccine for infectious diseases. Drug Metab. Pharmacokinet. 42, 100432 (2022).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"9451_CR31","doi-asserted-by":"publisher","first-page":"e0157821","DOI":"10.1128\/jvi.01578-21","volume":"96","author":"K Cao","year":"2022","unstructured":"Cao, K. et al. A single vaccine protects against SARS-CoV-2 and influenza virus in mice. J. Virol. 96, e0157821 (2022).","journal-title":"J. Virol."},{"key":"9451_CR32","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/mt.2012.248","volume":"21","author":"D Zhou","year":"2013","unstructured":"Zhou, D. et al. Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus. Mol. Ther. 21, 696\u2013706 (2013).","journal-title":"Mol. Ther."},{"key":"9451_CR33","doi-asserted-by":"publisher","first-page":"eadu7646","DOI":"10.1126\/scitranslmed.adu7646","volume":"17","author":"C Jacob-Dolan","year":"2025","unstructured":"Jacob-Dolan, C. et al. Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques. Sci. Transl. Med. 17, eadu7646 (2025).","journal-title":"Sci. Transl. Med."},{"key":"9451_CR34","doi-asserted-by":"publisher","first-page":"e0067423","DOI":"10.1128\/jvi.00674-23","volume":"97","author":"JA Misplon","year":"2023","unstructured":"Misplon, J. A., Lo, C. Y., Crabbs, T. A., Price, G. E. & Epstein, S. L. Adenoviral-vectored universal influenza vaccines administered intranasally reduce lung inflammatory responses upon viral challenge 15 months post-vaccination. J. Virol. 97, e0067423 (2023).","journal-title":"J. Virol."},{"key":"9451_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184.e113 (2020).","journal-title":"Cell"},{"key":"9451_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"9451_CR37","first-page":"100603","volume":"5","author":"Z Zhang","year":"2024","unstructured":"Zhang, Z. et al. A causal multiomics study discriminates the early immune features of Ad5-vectored Ebola vaccine recipients. Innovation 5, 100603 (2024).","journal-title":"Innovation"},{"key":"9451_CR38","doi-asserted-by":"publisher","unstructured":"Lacabaratz, C. et al. Innate and cellular immune response to the Ebola vaccine Ad26.ZEBOV, MVA-BN-Filo: an ancillary study of the EBL2001 phase II trial. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiae360 (2024).","DOI":"10.1093\/infdis\/jiae360"},{"key":"9451_CR39","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.1016\/j.vaccine.2022.06.008","volume":"40","author":"PM Folegatti","year":"2022","unstructured":"Folegatti, P. M. et al. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: standardized template with key considerations for a risk\/benefit assessment. Vaccine 40, 5248\u20135262 (2022).","journal-title":"Vaccine"},{"key":"9451_CR40","doi-asserted-by":"publisher","first-page":"e3548","DOI":"10.1371\/journal.pone.0003548","volume":"3","author":"MA Croyle","year":"2008","unstructured":"Croyle, M. A. et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3, e3548 (2008).","journal-title":"PLoS ONE"},{"key":"9451_CR41","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1128\/JVI.02864-12","volume":"87","author":"JS Richardson","year":"2013","unstructured":"Richardson, J. S., Pillet, S., Bello, A. J. & Kobinger, G. P. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J. Virol. 87, 3668\u20133677 (2013).","journal-title":"J. Virol."},{"key":"9451_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00959-0","volume":"9","author":"JP Casazza","year":"2024","unstructured":"Casazza, J. P. et al. Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine. npj Vaccines 9, 171 (2024).","journal-title":"npj Vaccines"},{"key":"9451_CR43","doi-asserted-by":"publisher","unstructured":"Steel, J. et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1, https:\/\/doi.org\/10.1128\/mBio.00018-10 (2010).","DOI":"10.1128\/mBio.00018-10"},{"key":"9451_CR44","doi-asserted-by":"publisher","first-page":"13434","DOI":"10.1128\/JVI.01429-12","volume":"86","author":"G Bommakanti","year":"2012","unstructured":"Bommakanti, G. et al. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J. Virol. 86, 13434\u201313444 (2012).","journal-title":"J. Virol."},{"key":"9451_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1073\/pnas.1308701110","volume":"111","author":"Y Lu","year":"2014","unstructured":"Lu, Y., Welsh, J. P. & Swartz, J. R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl. Acad. Sci. USA 111, 125\u2013130 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9451_CR46","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.immuni.2022.10.015","volume":"55","author":"SM Moin","year":"2022","unstructured":"Moin, S. M. et al. Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses. Immunity 55, 2405\u20132418 e2407 (2022).","journal-title":"Immunity"},{"key":"9451_CR47","doi-asserted-by":"publisher","unstructured":"Nagashima, K. A. & Mousa, J. J. Next-generation influenza HA immunogens and adjuvants in pursuit of a broadly protective vaccine. Viruses 13, https:\/\/doi.org\/10.3390\/v13040546 (2021).","DOI":"10.3390\/v13040546"},{"key":"9451_CR48","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.1128\/JVI.00641-13","volume":"87","author":"F Krammer","year":"2013","unstructured":"Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542\u20136550 (2013).","journal-title":"J. Virol."},{"key":"9451_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4049\/immunohorizons.1900022","volume":"3","author":"A Choi","year":"2019","unstructured":"Choi, A. et al. Chimeric hemagglutinin-based influenza virus vaccines induce protective stalk-specific humoral immunity and cellular responses in mice. Immunohorizons 3, 133\u2013148 (2019).","journal-title":"Immunohorizons"},{"key":"9451_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.15","volume":"1","author":"R Nachbagauer","year":"2016","unstructured":"Nachbagauer, R. et al. A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. npj Vaccines 1, 16015 (2016).","journal-title":"npj Vaccines"},{"key":"9451_CR51","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1128\/JVI.00137-12","volume":"86","author":"R Hai","year":"2012","unstructured":"Hai, R. et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86, 5774\u20135781 (2012).","journal-title":"J. Virol."},{"key":"9451_CR52","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899\u2013904 (2022).","journal-title":"Science"},{"key":"9451_CR53","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cell.2015.10.004","volume":"163","author":"GD Victora","year":"2015","unstructured":"Victora, G. D. & Wilson, P. C. Germinal center selection and the antibody response to influenza. Cell 163, 545\u2013548 (2015).","journal-title":"Cell"},{"key":"9451_CR54","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/infdis\/jir436","volume":"204","author":"DF Hoft","year":"2011","unstructured":"Hoft, D. F. et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J. Infect. Dis. 204, 845\u2013853 (2011).","journal-title":"J. Infect. Dis."},{"key":"9451_CR55","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","volume":"211","author":"SH Hodgson","year":"2015","unstructured":"Hodgson, S. H. et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J. Infect. Dis. 211, 1076\u20131086 (2015).","journal-title":"J. Infect. Dis."},{"key":"9451_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1128\/IAI.00740-09","volume":"78","author":"A Reyes-Sandoval","year":"2010","unstructured":"Reyes-Sandoval, A. et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect. Immun. 78, 145\u2013153 (2010).","journal-title":"Infect. Immun."},{"key":"9451_CR57","doi-asserted-by":"publisher","first-page":"eadg3469","DOI":"10.1126\/sciadv.adg3469","volume":"9","author":"MZM Zheng","year":"2023","unstructured":"Zheng, M. Z. M. et al. Single-cycle influenza virus vaccine generates lung CD8(+) Trm that cross-react against viral variants and subvert virus escape mutants. Sci. Adv. 9, eadg3469 (2023).","journal-title":"Sci. Adv."},{"key":"9451_CR58","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41577-023-00853-1","volume":"23","author":"E Rotrosen","year":"2023","unstructured":"Rotrosen, E. & Kupper, T. S. Assessing the generation of tissue resident memory T cells by vaccines. Nat. Rev. Immunol. 23, 655\u2013665 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"9451_CR59","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","volume":"21","author":"S Wu","year":"2021","unstructured":"Wu, S. et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect. Dis. 21, 1654\u20131664 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"9451_CR60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer, K. J. et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat. Med. 27, 270\u2013278 (2021).","journal-title":"Nat. Med."},{"key":"9451_CR61","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4049\/jimmunol.170.1.613","volume":"170","author":"S Schwaiger","year":"2003","unstructured":"Schwaiger, S., Wolf, A. M., Robatscher, P., Jenewein, B. & Grubeck-Loebenstein, B. IL-4-producing CD8+ T cells with a CD62L++(bright) phenotype accumulate in a subgroup of older adults and are associated with the maintenance of intact humoral immunity in old age. J. Immunol. 170, 613\u2013619 (2003).","journal-title":"J. Immunol."},{"key":"9451_CR62","doi-asserted-by":"publisher","first-page":"e0072423","DOI":"10.1128\/jvi.00724-23","volume":"97","author":"M Xing","year":"2023","unstructured":"Xing, M. et al. Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants. J. Virol. 97, e0072423 (2023).","journal-title":"J. Virol."},{"key":"9451_CR63","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1016\/j.vaccine.2016.08.066","volume":"34","author":"T Cheng","year":"2016","unstructured":"Cheng, T. et al. Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1. Vaccine 34, 4875\u20134883 (2016).","journal-title":"Vaccine"},{"key":"9451_CR64","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbrc.2018.05.148","volume":"502","author":"A Muralidharan","year":"2018","unstructured":"Muralidharan, A. et al. Identification of immunodominant CD8 epitope in the stalk domain of influenza B viral hemagglutinin. Biochem. Biophys. Res. Commun. 502, 226\u2013231 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"9451_CR65","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3201\/eid1910.130728","volume":"19","author":"C Qiu","year":"2013","unstructured":"Qiu, C. et al. Safe pseudovirus-based assay for neutralization antibodies against influenza A(H7N9) virus. Emerg. Infect. Dis. 19, 1685\u20131687 (2013).","journal-title":"Emerg. Infect. Dis."},{"key":"9451_CR66","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"9451_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00857-5","volume":"9","author":"M Xing","year":"2024","unstructured":"Xing, M. et al. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza. npj Vaccines 9, 64 (2024).","journal-title":"npj Vaccines"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09451-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T14:03:11Z","timestamp":1770300191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09451-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9451"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-09451-4","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}